Revlimid

Myelodysplastic Syndrome, Hemopoietic stem cell transplant, Lymphoma + 10 more
Treatment
15 FDA approvals
20 Active Studies for Revlimid

What is Revlimid

LenalidomideThe Generic name of this drug
Treatment SummaryLenalidomide is a prescription drug used to treat certain types of cancer, such as multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma. Lenalidomide belongs to a class of drugs called immunomodulatory imide drugs, which work by promoting malignant cell death and enhancing the body's immunity. It is usually taken orally in capsule form and is only available under a special restricted distribution program. Lenalidomide is much safer and more effective than its predecessor, thalidomide, and has fewer side effects and toxic
Revlimidis the brand name
image of different drug pills on a surface
Revlimid Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Revlimid
Lenalidomide
2005
70

Approved as Treatment by the FDA

Lenalidomide, also known as Revlimid, is approved by the FDA for 15 uses which include Myelodysplastic Syndromes (MDS) and Mantle Cell Lymphoma (MCL) .
Myelodysplastic Syndromes (MDS)
Mantle Cell Lymphoma (MCL)
Multiple Myeloma (MM)
Used to treat Multiple Myeloma (MM) in combination with Dexamethasone
Marginal Zone Lymphoma (MZL)
Used to treat Marginal Zone Lymphoma (MZL) in combination with Rituximab
Transfusion-dependent Anemia
Mantle Cell Lymphoma
Multiple Myeloma
Used to treat Multiple Myeloma (MM) in combination with Dexamethasone
Follicular Lymphoma
Used to treat Follicular Lymphoma ( FL) in combination with Rituximab
previously treated
In adults whose disease has relapsed with Rituximab
Myelodysplastic Syndrome
Hemopoietic stem cell transplant
Used to treat post-autologous hematopoietic stem cell transplantation in combination with Dexamethasone
Anemia
Lymphoma
Used to treat Marginal Zone Lymphoma (MZL) in combination with Rituximab
at least two prior systemic chemotherapy regimens
Lymphoma

Effectiveness

How Revlimid Affects PatientsLenalidomide is a drug used to treat hematological malignancies, which are cancers of the blood and bone marrow. It works in two ways - directly and indirectly. Directly, it kills cancer cells and slows down tumor growth, while also stopping cancer cells from invading other tissues. Indirectly, it reduces inflammation by blocking pro-inflammatory proteins. It also works to strengthen the immune system by increasing T cell production and natural killer cell activity. Lenalidomide has been studied for its potential to treat other diseases such as amyotrophic lateral sclerosis (ALS).
How Revlimid works in the bodyLenalidomide has many effects on the body. It works to weaken cancer cells by breaking down molecules that help them survive and reproduce. It also decreases inflammation by slowing down the production of molecules that cause swelling and discomfort. Lenalidomide also works to prevent the spread of cancer cells by stopping the cells from sticking together and moving around the body. Lastly, it prevents tumor growth by stopping blood vessels from supplying them with nutrients.

When to interrupt dosage

The advised dose of Revlimid is contingent upon the determined condition, including Mantle Cell Lymphoma, Relapsed and/or Refractory Lymphoma and Refractory Diffuse Large B Cell Lymphoma (DLBCL). The amount of dosage relies upon the technique of delivery (e.g. Capsule - Oral or Oral) stipulated in the table beneath.
Condition
Dosage
Administration
Myelodysplastic Syndrome
5.0 mg, 15.0 mg, 2.5 mg, 25.0 mg, 10.0 mg, 7.5 mg, , 20.0 mg
, Capsule - Oral, Capsule, Oral
Hemopoietic stem cell transplant
5.0 mg, 15.0 mg, 2.5 mg, 25.0 mg, 10.0 mg, 7.5 mg, , 20.0 mg
, Capsule - Oral, Capsule, Oral
Lymphoma
5.0 mg, 15.0 mg, 2.5 mg, 25.0 mg, 10.0 mg, 7.5 mg, , 20.0 mg
, Capsule - Oral, Capsule, Oral
Chronic Lymphocytic Leukemia
5.0 mg, 15.0 mg, 2.5 mg, 25.0 mg, 10.0 mg, 7.5 mg, , 20.0 mg
, Capsule - Oral, Capsule, Oral
Multiple Myeloma
5.0 mg, 15.0 mg, 2.5 mg, 25.0 mg, 10.0 mg, 7.5 mg, , 20.0 mg
, Capsule - Oral, Capsule, Oral
Lymphoma, B-Cell
5.0 mg, 15.0 mg, 2.5 mg, 25.0 mg, 10.0 mg, 7.5 mg, , 20.0 mg
, Capsule - Oral, Capsule, Oral
Mantle Cell Lymphoma
5.0 mg, 15.0 mg, 2.5 mg, 25.0 mg, 10.0 mg, 7.5 mg, , 20.0 mg
, Capsule - Oral, Capsule, Oral
Lymphoma
5.0 mg, 15.0 mg, 2.5 mg, 25.0 mg, 10.0 mg, 7.5 mg, , 20.0 mg
, Capsule - Oral, Capsule, Oral
Anemia
5.0 mg, 15.0 mg, 2.5 mg, 25.0 mg, 10.0 mg, 7.5 mg, , 20.0 mg
, Capsule - Oral, Capsule, Oral
at least two prior systemic chemotherapy regimens
5.0 mg, 15.0 mg, 2.5 mg, 25.0 mg, 10.0 mg, 7.5 mg, , 20.0 mg
, Capsule - Oral, Capsule, Oral
previously treated
5.0 mg, 15.0 mg, 2.5 mg, 25.0 mg, 10.0 mg, 7.5 mg, , 20.0 mg
, Capsule - Oral, Capsule, Oral
Follicular Lymphoma
5.0 mg, 15.0 mg, 2.5 mg, 25.0 mg, 10.0 mg, 7.5 mg, , 20.0 mg
, Capsule - Oral, Capsule, Oral
Amyloidosis
5.0 mg, 15.0 mg, 2.5 mg, 25.0 mg, 10.0 mg, 7.5 mg, , 20.0 mg
, Capsule - Oral, Capsule, Oral

Warnings

Revlimid Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Lenalidomide may interact with Pulse Frequency
There are 20 known major drug interactions with Revlimid.
Common Revlimid Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Lenalidomide is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Lenalidomide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Acteoside.
Revlimid Toxicity & Overdose RiskThe lowest lethal dose of lenalidomide in rats is greater than 2000 mg/kg when taken by mouth and greater than 40 mg/kg when given intravenously. In humans, the lowest toxic dose is 9 mg/kg taken over 4 weeks. There have been reports of serious side effects due to lenalidomide overdosing, including risks to the fetus, low blood cell counts, blood clots, heart problems, cancer, liver damage, skin reactions, abnormal thyroid levels, and tumour flare reactions.
image of a doctor in a lab doing drug, clinical research

Revlimid Novel Uses: Which Conditions Have a Clinical Trial Featuring Revlimid?

426 active studies are currently being conducted to assess the potential of Revlimid to treat previously treated, Relapsed and/or Refractory Lymphoma and Multiple Myeloma.
Condition
Clinical Trials
Trial Phases
Myelodysplastic Syndrome
127 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Phase 4
Lymphoma, B-Cell
36 Actively Recruiting
Phase 1, Phase 2, Phase 3, Early Phase 1
Multiple Myeloma
6 Actively Recruiting
Phase 1, Phase 2
Lymphoma
0 Actively Recruiting
Hemopoietic stem cell transplant
0 Actively Recruiting
Amyloidosis
1 Actively Recruiting
Not Applicable
Chronic Lymphocytic Leukemia
19 Actively Recruiting
Phase 2, Phase 1
Lymphoma
41 Actively Recruiting
Phase 2, Phase 1, Phase 3, Early Phase 1, Not Applicable
Follicular Lymphoma
80 Actively Recruiting
Phase 3, Not Applicable, Phase 2, Phase 1, Early Phase 1
Anemia
0 Actively Recruiting
at least two prior systemic chemotherapy regimens
0 Actively Recruiting
Mantle Cell Lymphoma
73 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1
previously treated
0 Actively Recruiting

Revlimid Reviews: What are patients saying about Revlimid?

5Patient Review
1/21/2014
Revlimid for Multiple Myeloma
My 90 year old husband has been on revlimid since Jan.'09 and it's working great! We've seen a significant reduction in tumors with very few side effects.
5Patient Review
7/21/2013
Revlimid for Multiple Myeloma
The only downside I've experienced is neuropathy in my feet, but it's worth it because I'm now able to walk more than four miles each day.
5Patient Review
7/28/2013
Revlimid for Multiple Myeloma
I have experienced some unfortunate side effects from this medication, including muscle cramps and worsening of my neuropathy.
5Patient Review
8/12/2014
Revlimid for Multiple Myeloma
The process of signing for the delivery while still working was a little difficult, but other than that everything went smoothly.
4.7Patient Review
8/11/2018
Revlimid for Multiple Myeloma
I've been on this drug for three years now and it has kept me alive. The downside is that I'm constantly tired and have developed neuropathy in both feet. Additionally, my skin has become thicker over time.
4.7Patient Review
8/1/2012
Revlimid for Multiple Myeloma
Even after aggressive treatment, my myeloma continued to worsen. Thankfully, this medication put me into remission within just a few months. It's now been over three years and I've only experienced minor side effects like irritable bowel syndrome and a metallic taste in my mouth.
4.7Patient Review
4/12/2012
Revlimid for Multiple Myeloma
This medication is great at lowering my white blood count.
4.7Patient Review
2/15/2012
Revlimid for Multiple Myeloma
4.7Patient Review
10/8/2014
Revlimid for Multiple Myeloma
This drug has been working great for me with no noticeable side effects.
4.3Patient Review
6/23/2013
Revlimid for Multiple Myeloma
I had a stem cell transplant in May of 2011 and I'm doing really well now. I've been on Revlimid since then with very few side effects. The only thing is that I get tired more easily, but it has gotten better over time.
4Patient Review
11/3/2014
Revlimid for Multiple Myeloma
I was diagnosed with MM in 2008 and have since tried stem cell transfer, CDT, Velcade, and Revlimid. The latter is the only one that has worked for me; I'm on my 32nd cycle now. That said, it does come with some not-so-great side effects like IBS and facial rash. Recently had a blood clot but thankfully that's cleared up now. All things considered, I'm doing alright.
3.3Patient Review
11/28/2012
Revlimid for Multiple Myeloma
So far, the medication has been working well for me. I'm grateful.
2.7Patient Review
2/8/2012
Revlimid for Bone Marrow Disorders Occurring Before Leukemia
2.3Patient Review
4/11/2012
Revlimid for Multiple Myeloma
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about revlimid

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of cancer is Revlimid used for?

"Lenalidomide is a cancer drug, also known by the brand name Revlimid, which is used to treat myeloma and blood disorders known as myelodysplastic syndromes. It may also be used as part of clinical trials for other types of cancer. When used to treat myeloma, lenalidomide is usually combined with a steroid drug called dexamethasone."

Answered by AI

What is the success rate of Revlimid?

"After patients went through tandem autologous transplants, they were given Revlimid. Out of the patients that took Revlimid, 88% achieved at least a very good partial remission and 53% achieved a complete remission. The one-year survival for these patients was 92%."

Answered by AI

Is Revlimid a high risk medication?

"If you have questions about the Lenalidomide REMS, please call 1-888-geyercorp.

The side effects of REVLIMID (lenalidomide) may be very serious, including the risk to unborn babies, the risk of low blood counts, and blood clots. There are safety considerations that you need to be aware of before taking REVLIMID. That is why REVLIMID is only available through a restricted distribution program called Lenalidomide REMS. If you have questions about the Lenalidomide REMS, please call 1-888-geyercorp."

Answered by AI

What does Revlimid do to your body?

"Cancer cells are growth-slow or growth-stop by the medicine. The medicine is also used to treat anemia which is caused by blood/bone marrow disorders (myelodysplastic syndromes-MDS). By using this medicine, patients may not need blood transfusions as often."

Answered by AI

Is Revlimid a chemotherapy?

"The drug Lenalidomide, which is also known by its brand name Revlimid, is used to treat cancer. It is specifically used to treat myeloma, which is a cancer of the blood, as well as myelodysplastic syndromes, which are disorders of the blood. Lenalidomide may also be used in clinical trials for other types of cancer. When used to treat myeloma, it is often combined with another drug called dexamethasone, which is a steroid."

Answered by AI

Clinical Trials for Revlimid

Image of OHSU Knight Cancer Institute in Portland, United States.

Fludarabine + Cytarabine + Idarubicin + Venetoclax for Acute Myeloid Leukemia

18 - 65
All Sexes
Portland, OR
This phase II trial compares induction and consolidation therapy with fludarabine, cytarabine, idarubicin, and venetoclax to cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of acute myeloid leukemia (AML). Patients with AML often receive induction and consolidation therapy. Induction therapy is given first to get the patient's AML under control (remission). Consolidation therapy is given after the cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. Chemotherapy drugs, such as fludarabine, cytarabine, idarubicin, and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving fludarabine, cytarabine, idarubicin, and venetoclax for induction and consolidation therapy may be more effective in treating AML.
Phase 2
Waitlist Available
OHSU Knight Cancer InstituteCurtis A Lachowiez
Image of Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center in Cleveland, United States.

Rituximab + Tafasitamab + NK Cells for Non-Hodgkin's Lymphoma

18+
All Sexes
Cleveland, OH
This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. The purpose of this study is to identify the recommended dose of allogeneic NK cells in combination with IL-2, Tafasitamab and Rituximab for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. NK cells are an investigational (experimental) treatment which means they are not approved by the Food and Drug Administration (FDA). NK cells are a type of lymphocyte that's part of the body's natural immune system, and they can kill cancer cells by creating pores in the cancer cell membranes and inducing apoptosis (programmed cell death). Participants in this study will receive lymphodepleting chemotherapy, as well as Allogeneic NK cells, Tafasitamab and Interleukin-2 (IL-2) by an intravenous (IV) infusion. Participants are expected to complete one cycle, and they may be eligible to complete a second cycle of the same regiment if they have stable disease, partial or complete remission at the end of the first cycle. Participants will be in this study for about 12 months.
Phase 1
Waitlist Available
Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center (+1 Sites)Paolo Caimi, MDIncyte Corporation
Have you considered Revlimid clinical trials? We made a collection of clinical trials featuring Revlimid, we think they might fit your search criteria.Go to Trials
Image of Ohio State University Comprehensive Cancer Center in Columbus, United States.

TriCAR19.20.22 T Cells for Blood Cancers

18+
All Sexes
Columbus, OH
This phase I trial tests the safety, side effects and best dose of anti-CD19/20/22 chimeric antigen receptor (CAR) T cells (TriCAR19.20.22 T cells) and how well they work in treating patients with non-Hodgkin lymphoma, acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein, such as CD19, CD20 and CD22, on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving TriCAR19.20.22 T cells may be safe, tolerable, and/or effective in treating patients with relapsed or refractory non-Hodgkin lymphoma, ALL and CLL.
Phase 1
Waitlist Available
Ohio State University Comprehensive Cancer CenterSumithira Vasu, MD
Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

ST-067 + CAR T-cell Therapy for Large B-Cell Lymphoma

18+
All Sexes
Seattle, WA
This phase I/II trial tests the safety, side effects, and best dose/regimen of ST-067 in combination with CD19-directed chimeric antigen receptor (CAR) T-cell therapy (liso-cel) and how well it works in treating patients with large B-cell lymphoma (LBCL) that has come back after a period of improvement (recurrent) or LBCL that has not responded to previous treatment (refractory). ST-067 is an engineered variant of the human cytokine interleukin-18 that may help the immune system kill cancer cells. Lisocabtagene maraleucel (liso-cel) is an autologous CAR T-cell therapy prepared using the person's own immune system (a group of cells, tissues, and organs that protect the body from attack by bacteria, viruses, and cancer cells) to fight the cancer. Giving ST-067 in combination with liso-cel may better treat patients with relapsed/refractory LBCL.
Phase 1 & 2
Recruiting
Fred Hutch/University of Washington Cancer ConsortiumAlexandre V. Hirayama, MD
Have you considered Revlimid clinical trials? We made a collection of clinical trials featuring Revlimid, we think they might fit your search criteria.Go to Trials
Image of City of Hope Medical Center in Duarte, United States.

Fecal Microbiota Transplantation for Lymphoma

18+
All Sexes
Duarte, CA
This phase II trial tests how well fecal microbiome transplantation works to remodel intestinal microbiota for patients with lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) with exposure to high-risk antibiotics who are receiving chimeric antigen receptor (CAR) T cells. Fecal microbiome transplantation consists of fecal microbiota from healthy donors with healthy gut microbiota that allows re-population of the patient's microbiome with diverse protective microorganisms. CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Part of the treatment for CAR T therapy involves high doses of chemotherapy. This, along with prior exposure to high strength antibiotics, can damage patient's intestinal microbiota. Giving fecal microbiome transplantation may improve clinical response by repairing intestinal microbiota for patients with relapsed or refractory lymphoma who had exposure to high-risk antibiotics.
Phase 2
Waitlist Available
City of Hope Medical CenterKaramjeet S Sandhu
Image of Memorial Sloan Kettering Basking Ridge (All Protocol Activities) in Basking Ridge, United States.

Reduced Dose Radiation Therapy for Follicular Lymphoma

18+
All Sexes
Basking Ridge, NJ
The researchers are doing this study to find out whether a very low dose of radiation therapy (VLDRT) is an effective treatment for people with follicular lymphoma (FL) or marginal zone lymphoma (MZL) and works as well as the standard dose of radiation therapy. The researchers will see if VLDRT works against cancer in the area that is currently affected by cancer and if the therapy prevents new spots of lymphoma from developing. The researchers will also compare VLDRT with the standard dose of radiation therapy to see if VLDRT causes fewer side effects. Radiation therapy uses beams of intense energy to kill cancer cells. Standard doses of radiation therapy can cause short- and long-term side effects. Researchers think VLDRT may be as effective as standard doses, and, because VLDRT uses less radiation, researchers think VLDRT may cause fewer side effects than standard doses.
Phase 3
Recruiting
Memorial Sloan Kettering Basking Ridge (All Protocol Activities) (+6 Sites)Brandon Imber, MD
Image of City of Hope Medical Center in Duarte, United States.

CMV-MVA Triplex Vaccine for Cancer

18 - 75
All Sexes
Duarte, CA
This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cell transplantation (haploHCT) has advanced to become the predominant procedure for patients lacking a matched donor. Compared to matched related donor transplants, the rate of significant CMV infection is higher in patients undergoing a haploHCT. Significant CMV infection is associated with an increased risk of complications and death. Vaccination is the main preventative approach to limit complications and death in immunocompromised patients at high risk of post-stem cell transplant infections. CMV-MVA Triplex vaccine, is a CMV vaccine based on the attenuated poxvirus, modified vaccinia Ankara (MVA), developed to enhance CMV-specific immunity in both healthy stem cell transplant donors and stem cell transplant patients to prevent significant CMV infection post-stem cell transplant. Giving CMV-MVA triplex vaccine may be safe, tolerable and/or effective in enhancing cytomegalovirus (CMV)-specific immunity and preventing CMV viremia in patients undergoing a haploHCT.
Phase 1
Waitlist Available
City of Hope Medical Center (+2 Sites)Ryotaro Nakamura
Image of City of Hope Medical Center in Duarte, United States.

Emapalumab for Graft-versus-Host Disease

18 - 75
All Sexes
Duarte, CA
This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (GVHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after reduced-intensity donor (allogeneic) hematopoietic cell transplant (HCT). Giving chemotherapy, such as fludarabine, melphalan, or busulfan, before a donor \[peripheral blood stem cell\] transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When healthy stem cells for a donor are infused into a patient (allogeneic HCT), they may help the patient's bone marrow make more healthy cells and platelets. Allogeneic HCT is an established treatment, however, GVHD continues to be a major problem of allogeneic HCT that can complicate therapy. GVHD is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Emapalumab binds to an immune system protein called interferon gamma. This may help lower the body's immune response and reduce inflammation. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill cancer cells. It may also lower the body's immune response. Tacrolimus is a drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants. Mycophenolate mofetil is a drug used to prevent GVHD after organ transplants. It is also being studied in the prevention of GVHD after stem cell transplants for cancer, and in the treatment of some autoimmune disorders. Mycophenolate mofetil is a type of immunosuppressive agent. Giving emapalumab with post-transplant cyclophosphamide, tacrolimus and mycophenolate mofetil may be safe, tolerable and/or effective in preventing GVHD in patients with AML or MDS after a reduced-intensity allogeneic HCT.
Phase 1
Waitlist Available
City of Hope Medical CenterAmandeep Salhotra
Have you considered Revlimid clinical trials? We made a collection of clinical trials featuring Revlimid, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security